Altria Group, Inc. (MO)
NYSE · Richmond, Virginia, USA · Founded 1847 · CEO Sal Mancuso
Valuation summary
$47.87 fair value versus $74.68 in the market, a difference of -35.9%. Rated Sell.
| Fair value per share | $47.87 |
| Current share price | $74.68 |
| Upside / downside | -35.9% |
| Bear case | $30.42 |
| Bull case | $72.00 |
| Discount rate (WACC) | 8.4% |
| Terminal growth | 1.50% |
| Market capitalisation | $124B |
| EV / Sales | 6.3x |
About Altria Group, Inc.
Traces to 1847 as Philip Morris in London; the US business separated from Philip Morris International in 2008 and renamed Altria. Sal Mancuso, previously chief financial officer, succeeded Billy Gifford as CEO in May 2026. Altria sells Marlboro and other cigarette brands exclusively in the United States, along with oral nicotine products including on! pouches and NJOY e-vapor. The business is in structural volume decline, offset by consistent price increases — a strategy that works until it does not.
Investment case
- Extraordinary margins and free cash flow conversion, funding one of the highest dividend yields in the S&P 500.
- Marlboro has held roughly 42% US cigarette share for decades, giving genuine pricing power.
- Regulatory barriers make new entry into cigarettes effectively impossible.
Key risks
- US cigarette volumes decline every year, and the rate of decline has been accelerating.
- Illicit disposable vapes have taken share and enforcement has been ineffective.
- Menthol ban proposals and nicotine reduction rules are existential regulatory risks.
Recent developments
- 2026-10-29 · Q3 EPS of $1.51 and revenue of $6.13bn beat as pricing offsets falling cigarette volumes; 2026 guidance raised and buyback expanded source
- 2026-08-27 · Altria raised its quarterly dividend 4.7% to $1.11 a share, a 6.4% yield, its 61st increase in 57 years source
- 2026-08-22 · Altria has repurchased about 22.4m shares for roughly $1.34bn under its current programme source
Revenue by segment
| Smokeable Products | 88% |
| Oral Tobacco | 11% |
| Other | 1% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $23.6B | $8.1B |
| Year 2 | $23.8B | $7.8B |
| Year 3 | $24.0B | $7.5B |
| Year 4 | $24.4B | $7.2B |
| Year 5 | $24.9B | $7.0B |
What the street says
An income holding where the entire argument is whether price increases can keep outrunning volume decline.
Comparable companies: BTI · MCD · HSY · SBUX · PM · UL · PG · NESN
Open the interactive model, price chart and sensitivity grid →